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Surana et al.1 describe a male patient admitted with a
provisional diagnosis of non-ST-elevation myocardial infarc-
tion. The authors state that the patient did not receive
clopidogrel because of substantial comorbidities. I disagree
with this approach. Clopidogrel, 300mg loading dose
followed by 75mg daily, should be added to aspirin in a
patient with unstable angina/non-ST-elevation myocardial
infarction.2,3 Even if a patient has a history of gastrointestinal
bleeding, clopidogrel plus aspirin can be administered with
proton pump inhibitors to minimize the risk of recurrent
gastrointestinal bleeding.2 Although the dialysis population is
usually excluded from trials in coronary artery disease,4 no
dosage adjustment is required for clopidogrel in a patient
with renal impairment.3
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To the Editor: In a recent interesting review regarding
etiologic mechanisms of stone formation,1 no mention was
made of the role of medullary sponge kidney (MSK),
characterized by ectasia and cystic formation in the medul-
lary collecting precalyceal ducts.
Recent findings and its association with different mal-
formative conditions suggest that MSK belongs to the category
of developmental disorder, resulting from the disruption of the
ureteric bud/metanephric-blastema interface, as evidenced by
the occasional presence of embryonal tissue in the affected
papillae.2 In addition to anatomic abnormalities, low levels
of urinary inhibitors of stones (citrate and magnesium)
and alterations of tubular handling of bicarbonate/calcium/
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Figure 1 | Stone formation in MSK. Scheme showing the typical urographic appearance of ‘pyramidal-blush/paint brush’ in the case
of (a) medullary sponge kidneys corresponding to the presence of (b) dilated precalyceal collecting ducts (c) with some cysts and
(d) ectasic areas of tubular structures well evident at light microscopy, which offer a favorable setting for crystal deposition.
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